19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
14:10 , May 18, 2018 |  BC Week In Review  |  Company News

Lilly continues to build cancer pipeline with AurKa acquisition

Eli Lilly and Co. (NYSE:LLY) signed another bolt-on deal to build its cancer pipeline, agreeing on May 14 to buy AurKa Pharma Inc. (Montreal, Quebec) for up to $575 million. The deal came just four...
15:27 , May 14, 2018 |  BC Extra  |  Company News

Lilly continues to build cancer pipeline with AurKa acquisition

Eli Lilly and Co. (NYSE:LLY) signed another bolt-on deal to build its cancer pipeline, agreeing Monday to buy AurKa Pharma Inc. (Montreal, Quebec) for up to $575 million. The deal comes just four days after...